Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 220

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 220
---
 of overlap                                                                               
 between the current HCPs that we target and HCPs who prescribe colchicine for gout, allowing for efficient dual promotion of GLOPERBA and ZTlido. The principal elements of the GLOPERBA strategy are as follows: |

| • |     | Educate the market on the need for and value of simplified and precise colchicine dose adjustments to allow                                                                                                                                       
 individualized, patient-by-patient therapy. Scilex will leverage its in-person sales forces, medical affairs teams, and                                                                                                                           
 omni-channel HCP engagement campaigns to drive awareness of GLOPERBA’s features and benefits. In addition, target providers, rheumatologists and primary care physicians treating various comorbidities, will be provided with tools to help them 
 identify and prescribe GLOPERBA to appropriate patients.                                                                                                                                                                                          |

| • |     | Increase access to GLOPERBA for subsets of patients in prophylactic treatment of gout, specifically those with                                                                   
 comorbidities and GI intolerance. Our managed healthcare account executives will negotiate contracts with key payer and pharmacy customers to achieve uptake of key formularies. |

| • |     | Develop and commercialize SEMDEXATM as a                                                                                                                                                                                                                
 novel epidural injection for the first approved treatment of sciatica. We are developing SEMDEXA to address the limitations associated with the available corticosteroid epidural injectable products that are used                                     
 off-label. Many of these products contain potentially neurotoxic preservatives and particulates, and are administered over 12 million times annually despite a warning on the label of serious neurologic                                               
 complications, including loss of vision, stroke, paralysis and death. These products carry warnings required by the FDA that the safety and efficacy of epidural administration has not been established. SEMDEXA has received fast track designation   
 from the FDA and, if approved, could become the first FDA-approved epidural steroid product with long-term patent protection, which we also believe would create significant barriers to entry. Although such                                           
 designation has been granted, it may not lead to a faster development or regulatory review process and such designation does not increase the likelihood that SEMDEXA will receive marketing approval. Due to the novelty of our formulation as well as 
 the associated patents and trade secrets, future potential competitors could be required to conduct extensive preclinical studies and costly comparative clinical trials. A full 6-month data analysis was                                              
 completed in February 2022 and we have completed a pivotal